Reference : Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le p...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Human health sciences : Cardiovascular & respiratory systems
Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le patient diabetique: reduction par des approches pharmacologiques systemiques.
[en] Incidence of restenosis and cardiac events after coronary angioplasty in diabetic patients: reduction by systemic pharmacological approaches
Nyssen, Anne-Sophie mailto [Université de Liège - ULg > Département Psychologies Cliniques et Systèmes Humains > Ergonomie et intervention au travail >]
Legrand, Victor mailto [Université de Liège - ULg > Département des sciences cliniques > Cardiologie >]
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques >]
Revue Médicale de Liège
Université de Liège
[en] Angioplasty, Balloon, Coronary/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/therapeutic use ; Belgium/epidemiology ; Cardiovascular Agents/therapeutic use ; Coronary Restenosis/epidemiology/prevention & control ; Coronary Thrombosis/therapy ; Diabetes Complications/prevention & control ; Diabetes Mellitus, Type 2/complications ; Drug Therapy, Combination ; Evidence-Based Medicine ; Fatty Acids, Omega-3/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Immunologic Factors/therapeutic use ; Incidence ; Meta-Analysis as Topic ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Stents
[en] Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients who are at increased risk for such complication. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse the role of antiplatelet agents, omega-3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants, glitazones and, finally, classical antidiabetic drugs such as metformin and insulin. Whenever possible, we will focus our attention on the results obtained in the diabetic population.
Students ; Professionals ; Researchers

File(s) associated to this reference

Fulltext file(s):

Open access
REV MED LG 200904_05 NYSSEN RISQUE DE RESTENOSE.pdfPublisher postprint457.65 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.